Despite its limitations, our report builds on current evidence that indicates that molecular pathology results in NEC may generate clinically important information in a substantial proportion of patients: two out of 12 NGS-tested patients harbored the BRAF V600E-mutation, and this was the only targetable mutation found. Here, BRAF is linked to neuroendocrine carcinoma.